Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss

The FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials. While vision is the first target, it could have applications for a variety of age-related disease.

Več na: https://www.wired.com/story/longevity-startup-doses-first-human-in-bid-to-reverse-age-related-sight-loss/

nazaj